The association between naltrexone treatment and symptoms of depression in opioid-dependent patients

American Journal of Drug and Alcohol Abuse

Volumn 37, Issue 1, 2011, Pages 22-26

  Mysels, David J ^a,b,c,d   Cheng, Wendy Y ^a,b   Nunes, Edward V ^a,b   Sullivan, Maria A ^a,b  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b Surgeons of Columbia University ^*  (United States)

^c Cambridge Health Alliance ^*  (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

depression; Hamilton Depression Rating Scale; naltrexone; opioid dependence

Indexed keywords

NALTREXONE;

ADULT; DEPRESSION; FEMALE; HAMILTON SCALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; REVIEW;

ADULT; AFFECT; DEPRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 79751520444     PISSN: 00952990     EISSN: 10979891     Source Type: Journal    
DOI: 10.3109/00952990.2010.540281     Document Type: Review

References (27)

1. Wang D, Sun X, Sadee W. Different effects of opiate antag-onists on mu-, delta-, and kappa-opiate receptors with and without agonist pretreatment. The J Pharmacol Exp Ther 2007; 321: 544-552. (Pubitemid 46624496)
2. Sullivan MA, Vosburg SK, Comer SD. Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects ofheroin. Psychopharmacology 2006; 189: 37-46. (Pubitemid 44607258)
3. O'Connor PG, Fiellin DA. Pharmacologic treatment of heroin-dependent patients. Ann of Intern Med 2000; 133: 40-54. (Pubitemid 30432543)
4. Kirchmayer U, Davoli M, Verster AD, Amato L, Ferri M, Perucci CA. A systematic review on the efficacy of naltrex-one maintenance treatment in opioid dependence. Addiction. 2002; 97: 1241-1249.
5. Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A. Oral naltrexone maintenance treatment for opi-oid dependence. Cochrane Database of Syst Rev 2006; (1): CD001333.
6. Sullivan MA, Rothenberg JL, Vosburg SK, Church SH, Feldman SJ, Epstein EM, Kleber HD, Nunes EV Predictors of retention in naltrexone maintenance for opioid dependence: analysis of a stage I trial. Am J Addict 2006; 15: 150-159.
7. Carpenter KM, Jiang H Sullivan MA, Bisaga A, Comer SD Raby WN, Brooks AC, Nunes EV Betting on change: model-ing transitional probabilities to guide therapy development for opioid dependence. Psychol Addict Behav 2009; 23: 47-55.
8. Miotto K, McCann M, Basch J, Rawson R, Ling W. Naltrexone and dysphoria: fact or myth? Am J Addict 2002; 11: 151-160. (Pubitemid 34538652)
9. Mendelson JH, Ellingboe J, Keuhnle JC, Mello NK. Effects of naltrexone on mood and neuroendocrine function in normal adultmales. Psychoneuroendocrinilogy 1979; 3: 231-236.
10. Hollister LE, Johnson K, Boukhabza D, Gillespie HK. Aversive effects of naltrexone in subjects not dependent on opiates. Drug and Alcohol Dependence. 1981; 8: 37-41. (Pubitemid 11004811)
11. Crowley TJ, Wagner JE, Zerbe G, Macdonald M. Naltrexone-induced dysphoria in former opioid addicts. Am J Psychiatry 1985; 142(9): 1081-1084. (Pubitemid 16250788)
12. Petrakis I, Ralevski E, Nich C, Levinson C, Carroll K, Poling J, Rounsaville B. Naltrexone and disulfiram in patients with alcohol dependence and current depression. J Clin Psychopharmacology 2007; 27(2): 160-165. (Pubitemid 46594932)
13. Dean AJ, Saunders JB, Jones RT, Young RM, Connor JP, Lawford BR. Does naltrexone treatment lead to depression? J Psychiatry and Neuroscis. 2006; 31(11): 38-45.
14. Rothenberg JL, Sullivan MA, Church SH, Seracini A, Collins E, Kleber HD, Nunes EV. Behavioral naltrexone therapy: an integrated treatment for opiate dependence. J Subst Abuse Treat 2002; 23(4):351-360. (Pubitemid 35477814)
15. Comer SD, Collins ED, Kleber HD, Nuwayser ES, Kerrigan JH, Fischman MW. Depot naltrexone: long-lasting antago-nism of the effects of heroin in humans. Psychopharmacology 2002; 159(4): 351-360. (Pubitemid 34143359)
16. Spitzer RL, Williams JB, Gibbon M, First MB. TheStructured Clinical Interview for DSM-III-R (SCID). I: history, rationale, and description". Arch Gen Psychiatry 1992; 49(8):624-629.
17. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. (SCID-I/P). New York: Biometrics Research, New York State Psychiatric Institute, November 2002.
18. Hamilton M. A rating scale for depression J Neurol, Neurosurg Psychiatry 1960; 23: 56-62.
19. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967; 6: 278-296.
20. Shafer AB. Meta-analysis of the factor structures of four depression questionnaires: Beck, CES-D, Hamilton, and Zung. J Clin Psychol. 2006; 62(1): 123-146.
21. Brady KT, Myrick H, Sonne S. Co-occurring addictive and affective disorders. In Principles of Addiction Medicine. (3rd ed.). Graham AW, Schultz TK, Mayo-Smith MF, Ries RR, Wilford BB,eds. Chevy Chase, MD: American Society of AddictionMedicine, 2003; 1277-1286.
22. Teesson M, Havard A, Fairbairn S, Ross J, Lynskey M, Darke S. Depression among entrants to treatment for heroin dependence in the Australian Treatment Outcome Study (ATOS): prevalence, correlates and treatment seeking. Drug and Alcohol Depend 2005; 78: 309-315. (Pubitemid 40694053)
23. Mintz J, O'brien CP, Woody G, Beck AT Depression in treated narcotic addicts, ex-addicts, nonaddicts, and suicide attempters. Am J Drug and Alcohol Abuse 1979; 6(4): 385-396.
24. Steer RA, Emery GD, Beck AT Correlates of self-reported and clinically assessed depression in male heroin addicts. J Clin Psychology 1980; 56(3): 798-800. (Pubitemid 10041074)
25. Woody GE, O'Brien CP, Rickels K. Depression and anxiety in heroin addicts: a placebo-controlled study of doxepin in com-bination with methadone. American Journal of Psychiatry, 1975; 132: 447-450.
26. Nunes EV, Quitkin FM, Donovan SJ, Deliyannides D, Ocepek-Welikson K, Koenig T, Brady R, McGrath PJ, Woody G. Imipramine treatment of opiate-dependent patients with depressive disorders. A placebo-controlled trial. Arch Gen Psychiatry 1998; 55: 153-160. (Pubitemid 28087601)
27. Stein MD, Solomon DA, Herman DS, Anthony JL, Ramsey SE, Anderson BJ, Miller IW. Pharmacotherapy plus psy-chotherapy for treatment of depression in active injection drug users. Arch Gen Psychiatry 2004; 61(2): 152-159. (Pubitemid 38146549)